Cargando…

Breast Radiotherapy-Related Cardiotoxicity. When, How, Why. Risk Prevention and Control Strategies

SIMPLE SUMMARY: Given that the majority of breast cancer patients receive adjuvant radiation therapy and/or systemic treatments that can enhance cardiovascular risk, it is imperative to consider a multidisciplinary approach to cardiovascular care and to develop strategies to identify and prevent rad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Díaz-Gavela, Ana Aurora, Figueiras-Graillet, Lourdes, Luis, Ángel Montero, Salas Segura, Juliana, Ciérvide, Raquel, del Cerro Peñalver, Elia, Couñago, Felipe, Arenas, Meritxell, López-Fernández, Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038596/ https://www.ncbi.nlm.nih.gov/pubmed/33916644 http://dx.doi.org/10.3390/cancers13071712

Ejemplares similares

Breast radiotherapy in elderly women: myths, controversies, and current techniques in the adjuvant setting
por: Díaz Gavela, Ana Aurora, et al.
Publicado: (2020)

Tumor staging using 3.0 T multiparametric MRI in prostate cancer: impact on treatment decisions for radical radiotherapy
por: Couñago, Felipe, et al.
Publicado: (2015)

Cáncer y cardiotoxicidad en la población transgénero
por: Figueiras-Graillet, Lourdes M.
Publicado: (2023)

Radiotherapy for ostheoarticular degenerative disorders: When nothing else works()
por: Álvarez, Beatriz, et al.
Publicado: (2019)

Preoperative Radio(Chemo)Therapy in Breast Cancer: Time to Switch the Perspective?
por: Montero, Angel, et al.
Publicado: (2022)

Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: a single center experience
por: Couñago, Felipe, et al.
Publicado: (2016)

Magnetic resonance imaging for prostate cancer before radical and salvage radiotherapy: What radiation oncologists need to know
por: Couñago, Felipe, et al.
Publicado: (2017)

Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions
por: Couñago, Felipe, et al.
Publicado: (2019)

Interventional Radiotherapy in Gynecological Cancer
por: Rovirosa, Angeles, et al.
Publicado: (2023)

Ceftolozane-tazobactam: When, how and why using it?
por: López, Inmaculada, et al.
Publicado: (2021)

Cardiovascular Safety of Anagrelide in Healthy Subjects: Effects of Caffeine and Food Intake on Pharmacokinetics and Adverse Reactions
por: Martínez-Sellés, Manuel, et al.
Publicado: (2012)

Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer
por: Marinko, Tanja, et al.
Publicado: (2014)

Radiotherapy-Induced Cardiotoxicity: The Role of Multimodality Cardiovascular Imaging
por: Podlesnikar, Tomaž, et al.
Publicado: (2022)

Mindfulness-Based Programs: Why, When, and How to Adapt?
por: Loucks, Eric B., et al.
Publicado: (2022)

New-onset atrial fibrillation and prognosis in nonagenarians after acute myocardial infarction
por: Martínez-Sellés, M., et al.
Publicado: (2013)

Laparostomy: why and when?
por: Leppäniemi, Ari K
Publicado: (2010)

Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer.
por: de Graaf, H., et al.
Publicado: (1997)

Editorial: Cardiotoxicity induced by radiotherapy and/or chemotherapy after cancer treatment
por: Boerma, Marjan, et al.
Publicado: (2022)

End-of-life care in a cardiology department: have we improved?
por: Ruiz-Garcia, Juan, et al.
Publicado: (2016)

Assessing Silent Cardiotoxicity in Long-Term Lymphoma Survivors Treated With Radiotherapy
por: Miller, Eric, et al.
Publicado: (2021)

Not if but when; no longer why but how
por: Piper, Ian
Publicado: (2007)

When Apnea Turns Terminal: When, How, Why?
por: Goldman, Alica M.
Publicado: (2021)

Stereotactic Body Radiotherapy for Early-Stage Non–Small Cell Lung Cancer: When and Why Is It Appropriate Therapy?
por: Mullins, Kim
Publicado: (2015)

Acute skin toxicity of ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost for early breast cancer
por: Montero, Angel, et al.
Publicado: (2023)

Are all prostate cancer patients "fit" for salvage radiotherapy?
por: González-San Segundo, Carmen, et al.
Publicado: (2020)

Quality assurance in radiotherapy: analysis of the causes of not starting or early radiotherapy withdrawal
por: Arenas, Meritxell, et al.
Publicado: (2014)

Biopsy of renal masses: when and why
por: Sahni, V. Anik, et al.
Publicado: (2009)

Stopping Antiepileptic Drugs: When and Why?
por: Hixson, John D.
Publicado: (2010)

Does the “Why” Tell Us the “When”?
por: Bechlivanidis, Christos, et al.
Publicado: (2013)

WHEN AND WHY OPERATE ELDERLY OBESE
por: NASSIF, Paulo Afonso Nunes, et al.
Publicado: (2015)

Birth Control: Why, When and How?
Publicado: (1940)

EUS and ampullary adenoma: Why? When?
por: Alvarez-Sánchez, María-Victoria, et al.
Publicado: (2016)

Data citation: what, when, why?
por: Lemberger, Thomas
Publicado: (2018)

Loss of Migraine: When, Why and How
por: Blau, J. N.
Publicado: (1987)

Surgical Stillness—When, Why, and How?
por: Rosenberg, Jacob, et al.
Publicado: (2019)

Research Funding—Why, When, and How?
por: Neema, Shekhar, et al.
Publicado: (2021)

Withdrawal from Dialysis: Why and When?
por: Bhojaraja, Mohan V, et al.
Publicado: (2021)

Immunotherapy in myeloma: Why, when and how?
por: van de Donk, Niels W.C.J.
Publicado: (2018)

Sarcopenia: how to measure, when and why
por: Tagliafico, Alberto Stefano, et al.
Publicado: (2022)

When and Why Cats Are Returned to Shelters
por: Mundschau, Vivian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p9r4h2fn7ifio61lnnj7k4hhu1